Sorrento Therapeutics, Inc.

SRNE · OTC
Analyze with AI
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Activities
Net Income-$578-$429-$314-$363
Dep. & Amort.$13$12$11$11
Deferred Tax-$2-$36-$2-$0
Stock-Based Comp.$75$90$31$13
Change in WC$70-$3$4$7
Other Non-Cash$128$83$111$160
Operating Cash Flow-$294-$282-$160-$173
Investing Activities
PP&E Inv.-$14-$9-$38-$11
Net Acquisitions-$15-$1-$2-$10
Inv. Purchases$0-$35$0-$10
Inv. Sales/Matur.$0$125$0$0
Other Inv. Act.$0$0$0-$7
Investing Cash Flow-$29$80-$40-$38
Financing Activities
Debt Repay.-$92-$36-$187$22
Stock Issued$402$202$318$48
Stock Repurch.$0$0-$55$0
Dividends Paid$0$0$0$0
Other Fin. Act.$2$15$98$9
Financing Cash Flow$312$181$174$79
Forex Effect-$2$1$1-$0
Net Chg. in Cash-$13-$20-$24-$133
Supplemental Information
Beg. Cash$37$56$81$213
End Cash$24$37$56$81
Free Cash Flow-$308-$291-$197-$184
Sorrento Therapeutics, Inc. (SRNE) Financial Statements & Key Stats | AlphaPilot